Boston Scientific Shares Decline Following Full-Year Guidance Reduction
Boston Scientific (BSX) experienced a sharp decline in premarket trading on Wednesday despite reporting third-quarter 2026 financial results that exceeded analyst expectations. The downward pressure on the stock stems from the company's decision to lower its full-year guidance. The revised outlook is primarily attributed to the ongoing impact of a recent cybersecurity incident reported last month. While the quarterly performance showed strength, investors reacted negatively to the reduced long-term projections and the uncertainty surrounding the operational disruptions caused by the security breach.
Tickers: $BSX
Topics: cybersecurity incident earnings report financial outlook stock price movement
Read the full article at Seeking Alpha
Part of the story Rivian Shares Rise Following Q3 Revenue Beat and Increased Full-Year Guidance (6 articles)